

25 July 2023

Physiomics plc
(“PYC” or the “Company”)

Director Dealing

The Company announces that Dr Jim Millen, Chief Executive Officer of Physiomics, has transferred, for no consideration, 500,000 ordinary shares of 0.4p each in the Company held in certificated form (“Ordinary Shares”) to his nominee account with Interactive Investor Services Limited. The Ordinary Shares remain beneficially owned by Dr Millen.

Accordingly, Dr Millen’s total holding in the Company will remain unchanged at 1,884,393 Ordinary Shares, representing approximately 1.39 per cent. of the Company's issued share capital.

Enquiries:

Physiomics plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

Strand Hanson Ltd (NOMAD)

James Dance

James Bellman

+44 (0)20 7409 3494

The Company's LEI is 213800A71DSZ6ABMTQ91

PDMR Notification Forms

1.	Details of the person discharging managerial responsibilities / person closely associated	
a)	Name	James Millen
2.	Reason for the Notification	
a)	Position/status	Executive Chairman and CEO
b)	Initial notification/amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	Physiomics plc
b)	LEI	213800A71DSZ6ABMTQ91

4.	Details of the transaction(s):section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv)each place where transactions have been conducted					
a)	Description of the Financial instrument, type of instrument	Physiomics plc Ordinary Shares				
	Identification code	ISIN: GB00BDR6W943				
b)	Nature of the Transaction	Transfer of securities held in paper share certificates to nominee account Interactive Investor Services Nominees Limited.				
c)	Price(s) and volume(s)	Dr Jim Millen <table border="1" data-bbox="772 555 1469 640"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>N/A</td> <td>500,000</td> </tr> </tbody> </table>	Price(s)	Volume(s)	N/A	500,000
Price(s)	Volume(s)					
N/A	500,000					
d)	Aggregated information - Aggregated volume - Price	500,000 N/A				
e)	Date of the transaction	22 July 2023				
f)	Place of the transaction	Off market transaction				

Notes to Editor

About Physiomics

Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions. The Company's Virtual Tumour™ technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics' technologies have been confirmed by over 100 projects, involving over 50 targets and 75 drugs, and has worked with clients such as Merck KGaA, Astellas, Merck & Co and Bicycle Therapeutics.